NCT02162784已完成2 期
An Open-Label, Randomized, Cross-Over Study to Evaluate the Dose Response of SYN006 HFA MDI in Asthma Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 3
- 主要终点
- The variation of study medications by the area under curve of FEV1 from 0 to 120 minutes (AUC0-120min ) after inhalation.
研究概览
简要总结
The objective of the study is to evaluate the dose response of SYN006 HFA MDI, which is a combination drug product of budesonide and procaterol hydrochloride, in asthma patients. Patients with mild to moderate asthma will be recruited. There will be two study medication administered in this study. The investigational medication is SYN006 (Budesonide/Procaterol hydrochloride, 180 mcg/10 mcg per inhalation) and the active comparative medication is Ventolin (Salbutamol sulfate 100 mcg per inhalation). The study medication will be administered by oral inhalation with the supervision of the investigator or a qualified staff.
详细描述
Three treatments will be administered in a patient:
- A. Two inhalations of Ventolin 100 mcg,
- B. One inhalation of SYN006 180/10 mcg,
- C. Two inhalations of SYN006 180/10 mcg.
Patients will be received the study treatment according to one of the six treatment sequences according to the randomization schedule:
- A-B-C,
- B-A-C,
- C-A-B,
- C-B-A,
- A-C-B,
- B-C-A.
The efficacy endpoint is
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient aged >= 16 years old
- •History of FEV1 >=12% and 200 ml increase after inhalation of short-acting beta 2-agonist;
- •Pre-bronchodilator FEV1 > 60% and < 90% of predicted normal value at enrollment;
- •Ability to inhale correctly through MDI inhaler
- •Written informed consent obtained.
- •Diagnosis of mild to moderate persistent asthma according to GINA with a documented history of at least 6 months duration.
- •Mild Persistent:
- •Symptoms more than once a week but less than once a day
- •Nocturnal symptoms more than twice a month
- •Exacerbations may affect activity and sleep
- •FEV1 or PEF >= 80% predicted
- •PEF or FEV1 variability < 20 - 30%
- •Moderate Persistent:
- •Symptoms daily
- •Nocturnal symptoms more than once a week
- •Exacerbations may affect activity and sleep
- •Daily use of inhaled short-acting beta2-agonist
- •FEV1 or PEF > 60% - < 80% predicted
- •PEF or FEV1 variability > 30%
排除标准
- •Currently uncontrolled asthma according to GINA guideline;
- •Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;
- •Inability to carry out pulmonary function testing;
- •Severe asthma associated with reduced lung function;
- •Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer), neurological or haematological autoimmune diseases;
- •Abnormal ECG at enrollment;
- •History of near-fatal asthma and/or admission intensive care unit because of asthma;
- •History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias;
- •Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous 6 months at enrollment;
- •Hospitalization for asthma during the past 3 months at enrollment;
- •Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 3 months at enrollment;
- •Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years;
- •History of alcohol or drug abuse;
- •Pregnant or lactating females or not able to exclude pregnancy during the study period;
- •Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;
- •Patients who received any investigational new drug within the last 3 months at enrollment;
- •Patients who have been previously enrolled in this study.
研究组 & 干预措施
Budesonide/procaterol 180/10mcg X1
Experimental
HFA MDI, oral inhalation, 180/10mcg, one puff
干预措施: Budesonide/Procaterol, 180/10mcg X1 (Drug)
Budesonide/Procaterol, 180/10mcg X2
Experimental
HFA MDI, oral inhalation, two puffs
干预措施: Budesonide/procaterol 180/10 mcg X 2 (Drug)
Albuterol HFA MDI 100 mcg X2
Active Comparator
HFA MDI, oral inhalation, 100mcg, two puffs
干预措施: Albuterol HFA MDI 100mcg X2 (Drug)
结局指标
主要结局
The variation of study medications by the area under curve of FEV1 from 0 to 120 minutes (AUC0-120min ) after inhalation.
时间窗: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
次要结局
- The variation of study medications by the area under curve of PEFR from 0 to 120 minutes (AUC0-120min ) after inhalation.(5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation)
- The change in Forced Expiratory Volume in 1 second (FEV1) of study medication.(5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation)
- The change in Peak Expiratory Flow Rate (PEFR) of study medication.(5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation)
- The change in Forced Vital Capacity (FVC) of study medication.(5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation)
- The variation of study medications by the area under curve of FVC from 0 to 120 minutes (AUC0-120min ) after inhalation.(5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male SubjectsHealthy VolunteersNCT00879983Pfizer24
已完成
1 期
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)InfluenzaNCT00812019Seqirus753
已完成
1 期
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)Spinal Muscular AtrophyNCT01494701Biogen28
已完成
2 期
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsChronic Hepatitis C InfectionNCT01563536AbbVie (prior sponsor, Abbott)12
已完成
不适用
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly PeopleInfluenzaNCT01408290Fluart Innovative Vaccine Ltd, Hungary256